These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22841588)

  • 1. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure.
    Direz G; Noël N; Guyot C; Toupance O; Salmon JH; Eschard JP
    Joint Bone Spine; 2012 Dec; 79(6):631. PubMed ID: 22841588
    [No Abstract]   [Full Text] [Related]  

  • 2. IL-1 inhibition with anakinra in a patient with refractory gout.
    Singh D; Huston KK
    J Clin Rheumatol; 2009 Oct; 15(7):366. PubMed ID: 20009976
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.
    Loustau C; Rosine N; Forien M; Ottaviani S; Juge PA; Lioté F; Bardin T; Richette P; Dieudé P; Richez C; Bannwarth B; Schaeverbeke T; Ea HK; Truchetet ME
    Joint Bone Spine; 2018 Dec; 85(6):755-760. PubMed ID: 29654950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications of anakinra].
    Chauffier K; London J; Beaudouin C; Fautrel B
    Presse Med; 2009 May; 38(5):799-807. PubMed ID: 19278814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza A H1N1 and anakinra exposure in a patient with gout.
    Nocturne G; Ora J; Ea HK; Lioté F
    Joint Bone Spine; 2010 Jul; 77(4):369-70. PubMed ID: 20554240
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia.
    Bartov JB; Ali Y
    J Clin Rheumatol; 2013 Dec; 19(8):454-6. PubMed ID: 24263151
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Calvo-Aranda E; Sanchez-Aranda FM
    Rheumatology (Oxford); 2021 Nov; 60(11):e375-e377. PubMed ID: 34009241
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of Anakinra in Acute Gout: A Retrospective Review of Initial and Refractory Therapy.
    Petite SE
    Am J Ther; 2017; 24(5):e633-e634. PubMed ID: 27763889
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis.
    Liew JW; Gardner GC
    J Rheumatol; 2019 Oct; 46(10):1345-1349. PubMed ID: 30647192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra's efficacy is variable in refractory gout: report of ten cases.
    Chen K; Fields T; Mancuso CA; Bass AR; Vasanth L
    Semin Arthritis Rheum; 2010 Dec; 40(3):210-4. PubMed ID: 20494407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL1 inhibition in gout-where are we a decade on?
    So A
    Arthritis Res Ther; 2019 Nov; 21(1):233. PubMed ID: 31711537
    [No Abstract]   [Full Text] [Related]  

  • 12. Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
    Desmarais J; Chu CQ
    J Rheumatol; 2019 Jul; 46(7):748-750. PubMed ID: 30442822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anakinra in resistant gout: a case report.
    Van Wabeke J; Dhondt E; Peene I; Piette Y
    Acta Clin Belg; 2017 Aug; 72(4):293-295. PubMed ID: 27712511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case of anakinra as a steroid-sparing agent for gout inflammation.
    Gratton SB; Scalapino KJ; Fye KH
    Arthritis Rheum; 2009 Sep; 61(9):1268-70. PubMed ID: 19714614
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of anakinra in a case of refractory Still disease.
    Debiais S; Maillot F; Luca L; Buret J; Fautrel B; Renard JP
    J Clin Rheumatol; 2008 Dec; 14(6):357-8. PubMed ID: 19033875
    [No Abstract]   [Full Text] [Related]  

  • 16. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease.
    Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout.
    Tran AP; Edelman J
    Int J Rheum Dis; 2011 Aug; 14(3):e33-7. PubMed ID: 21816011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.
    Yilmaz S; Cinar M; Simsek I; Erdem H; Pay S
    Mod Rheumatol; 2014 Nov; 24(6):1030-1. PubMed ID: 24313885
    [No Abstract]   [Full Text] [Related]  

  • 19. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.
    Lutz V; Lipsker D
    Arch Dermatol; 2012 Mar; 148(3):297-9. PubMed ID: 22431771
    [No Abstract]   [Full Text] [Related]  

  • 20. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra.
    González-López MA; Martínez-Taboada VM; González-Vela MC; Fernández-Llaca H; Val-Bernal JF
    Br J Dermatol; 2008 May; 158(5):1146-8. PubMed ID: 18284383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.